Efficacy Trial on Meningococcal B Vaccine for Preventing Gonorrhea Infections

Launched by CHINESE UNIVERSITY OF HONG KONG · Mar 11, 2023

Keywords

ClinConnect Summary

This clinical trial is studying whether a meningococcal vaccine can help prevent gonorrhea infections in men who have sex with men (MSM). Gonorrhea is a common sexually transmitted infection (STI) that can be serious if not treated. The trial will take place in a teaching hospital in Hong Kong and is looking for 150 adult men who are at risk of getting gonorrhea. To qualify, you must be 18 years or older, have had condomless sex with multiple partners in the past six months, and have no history of gonorrhea vaccination.

Participants in the trial will receive either the meningococcal vaccine or a placebo (a harmless salt solution) in two doses, given one month apart. Throughout the study, researchers will monitor the participants for any gonorrhea infections and gather information about their sexual behavior. If you're eligible and choose to participate, you'll help contribute to important research that could lead to better strategies for preventing STIs in the future.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • Male adult who has had sex with another male in the past six months
• • Ages 18 years or above
• • Normally resides in Hong Kong
• • Able to communicate in written and spoken Chinese or English
• • At risk of gonorrhoea infection (had condomless sex with more than one man within the last six months, history of STI diagnosis, inclination to have condomless sex, and other PrEP-eligible criteria)
• • Negative NG test result at the time of recruitment
• • No history of previous vaccination with MenB vaccines
• • Able and willing to attend all study visits
• Exclusion Criteria:
• • Contraindications to receive MenB vaccine
• • Unable to give informed consent